Cite
HARVARD Citation
Wagner, T. et al. (n.d.). AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies. Annals of the rheumatic diseases. p. 1059. [Online].